ALS Patients Exhibit Reduced Cortical Volume, Thickness, and Cerebral Metabolism

In trying to determine the basis for volumetric changes seen in patients with amyotrophic lateral sclerosis (ALS), Drs. Venkateswaran Rajagopalan and Erik Pioro of the Cleveland Clinic have used voxel based morphometry to measure motor and extramotor grey matter volumes. The two recently delved into a study,…

  The accumulation of specific metals may trigger neuronal degeneration associated with Amyotrophic lateral sclerosis (ALS), according to a study conducted on residents of the Kii Peninsula in Japan. The study, titled, “Neutron Activation Analysis of Scalp Hair from ALS Patients and Residents in the Kii Peninsula, Japan” was…

A new clinical review entitled “Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?”, conducted by Christopher Donnelly from the Department of Neurology of the Johns Hopkins University and colleagues, explores the current status of Amyotrophic lateral sclerosis (ALS) evidence. The study was published…

Clinical-stage biopharmaceutical company Cytokinetics presented their lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), a novel skeletal muscle activator called tirasemtiv, in an oral presentation and four poster presentations, at the 25th International Symposium on ALS/MND, which took place between December 5 and…

The Muscular Dystrophy Association (MDA) and the ALS Association teamed up to fund a research project with a goal to find a potential therapy for amyotrophic lateral sclerosis (ALS or Lou Gehrig’sDisease). Both associations are nonprofit institutions committed to find cures and treatments for ALS, and to provide services to…

A professor at Boston University School of Medicine (BUSM), Carmela Abraham, PhD, recently received one of six Massachusetts Neuroscience Consortium Awards for 2014. Among 60 applications, her work on multiple sclerosis and the role of Klotho, a life extension protein, in the repair of white matter in the disease was selected…

The ALS Association recently announced that three new grants are being awarded to address unmet needs regarding the clinical management of amyotrophic lateral sclerosis (ALS). These funds will support research to benefit both ALS patients and caregivers by reducing unwanted weight loss in these patients, advancing techniques to improve their…

BrainStorm Cell Therapeutics Inc. will be holding a conference call and webcast session to discuss data regarding the company’s phase 2a clinical trial of NurOwn™ for amyotrophic lateral sclerosis (ALS). BrainStorm is a leading biotechnology company in the ALS space that is developing adult stem cell technologies to address neurodegenerative…

BrainStorm Cell Therapeutics Inc. received nearly $1.1 million in funding from Israel’s Office of the Chief Scientist (OCS) to support the development of NurOwn™, BrainStorm’s therapeutic platform for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). BrainStorm is a biotechnology company dedicated to the development of innovative adult…

The ALS Association announced that $326,662 will be used to fund new Amyotrophic Lateral Sclerosis (ALS) research. The new funding will seek to expand ongoing research projects to increase the knowledge of the most frequent genetic cause of the disease and support clinical trials dedicated to those that carry…